Eli Lilly (LLY)

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3% in the afternoon session after the company announced two deals, acquiri...

PPH offers the income and stability of proven pharmaceutical leaders while XBI swings for the fences across 155 smaller biotech names.

PPH concentrates on just 26 drugmakers, while IYH diversifies more broadly across 100 healthcare holdings.

Novo Nordisk, CVS Health, and Bristol Myers are top dividend stocks that are trading at modest valuations.

Outpatient physical therapy operators regularly strengthen their executive leadership to support long-term operational scaling and strategic financial mana

Investors can reap big rewards over the long term by betting on growth in their younger years.

The OmniAb Lilly Deal offers up to $370 million in milestones as OABI raises its 2026 cash outlook and shares jump premarket

The S&P 500 returned 9.5% annually over the past two decades. Wall Street expects much bigger gains in the next year.

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...

They are fairly risky, but their potential upside is massive.

The company's peers in the pharmaceutical industry should be worried.

They are way more than just GLP-1 stocks.

The U.K.'s health regulator just approved Eli Lilly's new weight-loss pill, a huge win for the drug maker.

Fidelity's lower 0.08% fee and broader 338-stock portfolio contrast sharply with iShares' concentrated pharma play, which delivered 60% returns in one year.

New product launches drove 5% revenue growth and margin expansion.

Active management and a charitable mission drive Simplify's 42% gain, but iShares offers lower costs and higher dividend income for conservative investors.

Fidelity's broad, low-cost index approach goes head-to-head with an actively managed, mission-driven healthcare fund.

The stock continues to look unstoppable.

It's yet another setback for the drugmaker.

FBT delivered 57.7% returns over one year but with nearly double the maximum drawdown. IYH offers lower costs and steadier performance for risk-averse investors.

Revenue surged 48% on Mounjaro and Zepbound demand, with full-year guidance raised.

VanEck targets established pharma giants with lower costs and volatility, while Invesco pursues high-growth biotech companies. One delivered stronger returns; the other weathered downturns better.

It has proven to be a market-beater in more years than not.

Eli Lilly filed six lawsuits against U.S. entities for illegally selling unapproved retatrutide, warning consumers of serious health risks.